Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes

Current Opinion in Rheumatology

Volumn 11, Issue 3, 1999, Pages 188-193

  Kobayashi, Tetsuya ^a   Okamoto, Kazuyoshi ^a   Kobata, Tetsuji ^a   Hasumuna, Tomoko ^a   Nishioka, Kusuki ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; FAS ANTIGEN; FAS LIGAND; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, RHEUMATOID; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; SYNOVIAL MEMBRANE;

EID: 0032992035     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199905000-00007     Document Type: Review

References (63)

1. 1 Harris ED: Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289.
2. 2 Stamenkovic I, Stegagno M, Wright KA, Krane SM, Amento EP, Colvin RB, et al.: Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A 1988, 85:1179-1183.
3. 3 O'Sullivan JB, Cathcart ES: The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972, 76:573-577.
4. 4 Feigenbaum SL, Masi AT, Kaplan SB: Prognosis in rheumatoid arthritis: a longitudinal study of newly diagnosed younger adult patients. Am J Med 1979, 66:377-384.
5. 5 Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, Nishioka K: Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995, 38:485-491.
6. 6 Firestein GS, Yeo M, Zvaifler NJ: Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995, 96:1631-1638.
7. 7 Hasunuma T, Hoa TTM, Aono H, Asahara H, Yonehara S, Yamamoto K, et al.: Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Int Immunol 1996, 8:1595-1602.
8. 8 Asahara H, Hasunuma T, Kobata T, Yagita H, Okumura K, Inoue H, et al.: Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 1996, 81:27-34.
9. 9 Okamoto K, Fujisawa K, Hasunuma T, Kobata T, Sumida T, Nishioka K: Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes. Arthritis Rheum 1997, 40:919-926.
10. 10 Deijard B, Hibi M, Wu I-H, Barrett T, Su B, Deng T, et al.: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76:1025-1037.
11. 11 Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al.: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994, 369:156-160.
12. 12 Davis RJ: MAPKs: new JNK expands the group. Trends Biochem Sci 1994, 19:470-473.
13. 13 Wilson DJ, Fortner KA, Lynch DH, Mattingly RR, Macara IG, Posada JA, Budd RC: JNK, but not MARK, activation is associated with Fas-mediated apoptosis in human T cells. Eur J Immunol 1996, 26:989-994.
14. 14 Latinis KM, Koretzky GA: Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells. Blood 1996, 87:871-875.
15. 15 Goillot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow E, Sanchez I: Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A 1997, 94:3303-3307.
16. 16 Juo P, Kuo CJ, Reynolds SE, Konz RF, Raingeaud J, Davis RJ, et al.: Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997, 17:24-35.
17. 17 Yang X, Khosravi-Far R, Chang HY, Baltimore D: Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997, 89:1067-1076.
18. 18 Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D: Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 1998, 281:1860-1863.
19. 19 Sato T, Irie S, Kitada S, Reed JC: FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415.
20. 20 Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoki T, Sawa E, et al.: The molecular interaction of Fas and FAP-1: a tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997, 272:8539-8545.
21. 21 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
22. 22 Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
23. 23 Stanger BZ, Leder P, Lee T-H, Kim E, Seed B: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995, 81:513-523.
24. 24 Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998, 281:1312-1316.
25. This review summarizes the role of caspases in the apoptotic process and proposes the potential treatment of several diseases by modulation of caspase molecules.
26. 25 Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997, 326:1-16.
27. 26 Ashkenazi A, Dixit V: Death receptor; signaling and modulation. Science 1998, 281:1305-1308.
28. This review summarizes the signaling pathway for apoptosis mediated via not only by Fas but also by other death receptors.
29. 27 Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997, 16:2794-2804.
30. 28 Peter ME, Kischkel FC, Hellbardt S, Chinnaiyan AM, Krammer PH, Dixit VM: CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differentiation 1996, 3:161-170.
31. 29 Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996, 85:803-815.
32. 30 Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al.: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
33. 31 Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al.: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
34. 2+-dependent endonuclease activity by nicotinamide adenine dinucleotide and poly(adenosine diphosphate ribose) synthetase. Biochem Biophys Res Commun 1974, 59:658-665.
35. 2+-dependent endonuclease. Proc Natl Acad Sci U S A 1975, 72:289-293.
36. 2+-dependent endonuclease of bull seminal plasma induced by ADP-ribosylation. J Biol Chem 1984, 259:6579-6585.
37. 35 Raff MC: Social controls on cell survival and cell death. Nature 1992, 356:397-400.
38. 36 Steller H: Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449.
39. 37 Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Sumida T, Nishioka K: Tumor necrosis factor-α regulation of Fas-mediated apoptosis-signaling pathway in synovial cells. Arthritis Rheum 1999, 42:519-526.
40. 38 Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1125-1132.
41. 39 Di Giovine FS, Nuki G, Duff GW: Tumor necrosis factor in synovial exudates. Ann Rheum Dis 1988, 47:768-772.
42. 40 Saxne T, Palladino MA Jr, Heinegád D, Talal N, Wollheim FA: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1998, 31:1041-1045.
43. 41 Alvaro-Gracia JM, Zvaifler NJ, Firestein GS: Cytokines in chronic inflammatory arthritis: V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990, 86:1790-1798.
44. 42 Butler DM, Piccoli DS, Hart PH, Hamilton JA: Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J Rheumatol 1988, 15:1463-1470.
45. 43 Gitter BD, Labus JM, Lees SL, Scheetz ME: Characteristics of human synovial fibroblast activation by IL-1β and TNFα. Immunology 1989, 66:196-200.
46. 44 Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K: Activation of transcription factor NF-ΚB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996, 39:197-203.
47. 45 Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al.: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
48. 46 Meinl E, Fickenscher H, Thome M, Tschopp J, Fleckenstein B: Anti-apoptotic strategies of lymphotropic viruses. Immunol Today 1998, 19:474-479.
49. 47 Hu S, Vincenz C, Ni J, Gentz R, Dixit VM: I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem 1997, 272:17255-17257.
50. 48 Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, et al.: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997, 272:18542-18545.
51. 49 Inohara N, Koseki T, Hu Y, Chen S, Núñez G: CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis, Proc Natl Acad Sci U S A 1997, 94:10717-10722.
52. 50 Shu H-B, Halpin DR, Goeddel DV: Casper is a FADD-and caspase-related inducer of apoptosis. Immunity 1997, 6:751-763.
53. 51 Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D: CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997, 272:19641-19644.
54. 52 Fujisawa K, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, et al.: Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice. J Clin Invest 1996, 98:271-278.
55. 53 Sakai K, Matsuno H, Morita I, Nezuka T, Tsuji H, Shirai T, et al.: Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. Arthritis Rheum 1998, 41:1251-1257.
56. 54 Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. : Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
57. 55 Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, et al.: Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995, 25:2253-2258.
58. 56 Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al.: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995, 182:1777-1783.
59. 57 Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T, et al.: Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 1998, 5:331-338.
60. This paper demonstrates that ex vivo Fas ligand gene transfer is useful against RA.
61. 58 Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T: Apoptosis in rheumatoid arthritis: A novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998, 41:1-9.
62. This is the first review to summarize the regulation of apoptic processes in rheumatoid synovial tissue closely associated with the pathogenesis and pathophysiology of RA.
63. 59 Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, et al.: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997, 100:1951-1957.